Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

275.26 +2.18 (+0.80%)
Streaming Delayed Price Updated: 10:10 AM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Amgen

< Previous 1 2 3 4 5 6 7 8 9
...
52 53 Next >
The Weight of Progress: A New Era Dawns for Anti-Obesity Drugs, Reshaping Markets and Health
The global anti-obesity drug market is experiencing an unprecedented surge, driven by groundbreaking advancements in pharmacotherapy, particularly the advent of highly effective GLP-1 receptor... 
Via MarketMinute
2 Healthcare Dividend Stocks to Buy and Hold
These drugmakers have competitive yields and have increased their dividends at a good clip. 
Via The Motley Fool
Topics Intellectual Property
The Dawn of a New Era: How GLP-1s, AI, and Robotic Surgery Are Reshaping Healthcare and Investment
The healthcare industry is currently experiencing a transformative "golden age," a period marked by an unprecedented surge in scientific breakthroughs and technological advancements. This era is... 
Via MarketMinute
Topics Artificial Intelligence Bankruptcy Economy
Zai Lab To Await More Trial Data Before Filing For Regulatory Approval For Experimental Cancer Drug
Via Stocktwits
1 Cash-Producing Stock to Target This Week and 2 Facing Challenges
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis
Amgen and Kyowa Kirin report positive interim results for rocatinlimab, showing long-term safety and sustained efficacy in moderate to severe atopic dermatitis patients. 
Via Benzinga
If You'd Invested $10,000 in Amgen Stock (AMGN) 3 Years Ago, Here's How Much You'd Have Today
You could have done worse -- or much better. 
Via The Motley Fool
Topics Economy
Nvidia Just Went Quantum—And ETFs Are Scrambling To Catch Up
Nvidia's $600M investment in Quantinuum highlights quantum computing's commercial evolution and may prompt new ETF strategies in the coming years. 
Via Benzinga
Topics ETFs
Why Is Sanofi Stock Falling Thursday?
William Blair notes OX40 antibodies rocatinlimab and amlitelimab trail Dupixent in efficacy, with dosing and side effects shaping their market potential. 
Via Benzinga
Amgen Faces Setback As Final Data Weakens Case For Gastric Cancer Drug
Amgen and Zai Lab's Phase 3 trial of bemarituzumab in gastric cancer showed a weaker survival benefit, shifting focus to the upcoming FORTITUDE-102 results. 
Via Benzinga
2 Safe-and-Steady Stocks to Keep an Eye On and 1 Facing Challenges
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
2 Profitable Stocks Worth Your Attention and 1 We Avoid
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
2 Dividend Stocks to Hold for the Next 10 Years
These stocks offer more than just dividends. 
Via The Motley Fool
Topics Economy
2 Large-Cap Stocks to Target This Week and 1 That Underwhelm
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth... 
Via StockStory
Deep Dive Into Amgen Stock: Analyst Perspectives (9 Ratings)
 
Via Benzinga
BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up
BeOne Medicines will sell global Imdelltra royalties to Royalty Pharma for up to $950 million while retaining rights to other oncology programs with Amgen. 
Via Benzinga
3 Dow Jones Dividend Stocks With Above-Average Yields You Can Buy Now and Hold for at Least a Decade
Some of the highest-yielding stocks in the Dow Jones Industrial Average index look like smart buys for income-seeking investors. 
Via The Motley Fool
Topics Stocks
3 Dow Jones Stocks to Keep an Eye On
The Dow Jones (^DJI) includes some of the most reliable stocks in the market, and while not all are equal, a few continue to shine. These companies are leveraging their strengths to maintain leadership... 
Via StockStory
Topics Artificial Intelligence Stocks
Warren Buffett, Cathie Wood Share 2 Stock Investments In Common: Can You Guess What They Are?
Cathie Wood looks for growth and companies on their way to big profits. Warren Buffett prefers looking for value and consistent profits. The two investors have two stock investments in common. 
Via Benzinga
Greenlight Capital Announces Q2 2025 Trades: New Positions in FLR and VSCO, Exit From VTRS
Greenlight Capital, led by David Einhorn, has disclosed its Q2 2025 13F filing trades. 
Via Benzinga
Is Eli Lilly Stock a Buy? Here's What the Market Isn't Pricing in Yet.
Viking Therapeutics' dual-formulation obesity drug could be the David to Lilly's Goliath. 
Via The Motley Fool
Topics Economy
Zevra Reported Its First-Ever Quarterly Profit. Why Shares Of The Top 6% Stock Crashed.
Zevra Therapeutics stock gapped down Wednesday after its first-ever quarterly profit missed even more bullish expectations. 
Via Investor's Business Daily
AMGN Q2 Deep Dive: Volume Growth, Pipeline Progress, and Guidance Raise Meet Investor Skepticism
Biotech company Amgen (NASDAQ:AMGN) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 9.4% year on year to $9.18 billion. The company’s full-year revenue guidance of $35.5 billion at... 
Via StockStory
Topics Artificial Intelligence
Eli Lilly Shares Tumble After Disappointing Weight-Loss Pill Data
Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a dramatic decline today, plummeting by more than 14% in early trading, wiping out approximately $98... 
Via MarketMinute
Eli Lilly Shares Tumble as Oral Weight-Loss Hope Falls Short of Lofty Expectations
Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a significant downturn, plummeting over 10% in premarket trading and continuing to slide throughout the... 
Via MarketMinute
Topics Economy
Amgen Stock Sinks As Market Eyes MariTide's Next Move
Amgen beat Q2 earnings and revenue expectations, raised 2025 guidance, and reported strong product sales growth across key therapies. 
Via Benzinga
Wall Street Recovers, Apple Rallies 6% On $100-Billion Gov Manufacturing Investment: What's Moving Markets Wednesday?
U.S. stocks rebounded sharply on Wednesday, fully erasing last Friday's losses, as upbeat corporate earnings and renewed investor optimism outweighed concerns over escalating trade tensions. 
Via Benzinga
RFK Jr. Sued By Eli Lilly, Amgen Over Drug Discount Program
Eli Lilly and Amgen are suing HHS over 340B certifications, claiming ineligible clinics cost them millions in lost revenue. 
Via Benzinga
Topics Lawsuit
Amgen Delivers Beat And Raise Quarter; Has Strong Late-Stage Pipeline
Amgen reported total revenue of $9.2 billion, topping the consensus of $8.9 billion, and non-GAAP earnings of $6.02 per share. 
Via Benzinga
AMGEN INC (NASDAQ:AMGN) Shows Strong Technical Breakout Potential with High Setup Rating
AMGEN INC (AMGN) shows strong breakout potential with a Technical Rating of 7 and Setup Rating of 9, signaling bullish momentum and a tight consolidation pattern. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
52 53 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.